HWM
ELTX icon

HB Wealth Management’s Elicio Therapeutics ELTX Stock Holding History

HB Wealth Management’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.9K Hold
10,463
– – ﹤0.01% 1685
2026
Q1 		$112K Buy
+10,463
New +$101K ﹤0.01% 1492

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

HB Wealth Management's ELTX Position: Q2 2026 in Review

HB Wealth Management held its Elicio Therapeutics (ELTX) position steady in Q2 2026 at 10,463 shares worth $40.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1685.

HB Wealth Management first reported a position in ELTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $112K in Q1 2026. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • HB Wealth Management held 10,463 shares of Elicio Therapeutics worth $40.9K as of Q2 2026.
  • HB Wealth Management left its Elicio Therapeutics share count unchanged in Q2 2026.
  • Elicio Therapeutics made up ﹤0.01% of HB Wealth Management's portfolio in Q2 2026, its #1685 holding.
  • HB Wealth Management first reported a position in Elicio Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • HB Wealth Management's Elicio Therapeutics position peaked at $112K in Q1 2026.
  • 48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on HB Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.